Several analysts have recently updated their ratings and price targets for DBV TECHNOLOGIE/S (NASDAQ: DBVT):

  • 5/23/2019 – DBV TECHNOLOGIE/S was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/14/2019 – DBV TECHNOLOGIE/S was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/8/2019 – DBV TECHNOLOGIE/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 5/7/2019 – DBV TECHNOLOGIE/S was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 4/12/2019 – DBV TECHNOLOGIE/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 4/10/2019 – DBV TECHNOLOGIE/S was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $10.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 4/5/2019 – DBV TECHNOLOGIE/S was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/27/2019 – DBV TECHNOLOGIE/S was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Shares of NASDAQ DBVT opened at $9.00 on Friday. DBV TECHNOLOGIE/S has a 12 month low of $3.60 and a 12 month high of $25.77. The company has a quick ratio of 3.30, a current ratio of 3.34 and a debt-to-equity ratio of 0.01. The stock has a market cap of $555.74 million, a PE ratio of -2.65 and a beta of 2.08.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley grew its holdings in shares of DBV TECHNOLOGIE/S by 23.5% during the first quarter. Morgan Stanley now owns 3,814,223 shares of the company’s stock worth $29,408,000 after purchasing an additional 724,863 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its position in DBV TECHNOLOGIE/S by 5.7% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 3,752,573 shares of the company’s stock worth $28,932,000 after buying an additional 202,882 shares during the last quarter. Bank of New York Mellon Corp lifted its position in DBV TECHNOLOGIE/S by 334.1% in the 4th quarter. Bank of New York Mellon Corp now owns 1,645,000 shares of the company’s stock worth $10,561,000 after buying an additional 1,266,041 shares during the last quarter. First Midwest Bank Trust Division lifted its position in DBV TECHNOLOGIE/S by 14.5% in the 1st quarter. First Midwest Bank Trust Division now owns 1,131,884 shares of the company’s stock worth $8,727,000 after buying an additional 142,993 shares during the last quarter. Finally, Perceptive Advisors LLC lifted its position in DBV TECHNOLOGIE/S by 36.5% in the 1st quarter. Perceptive Advisors LLC now owns 1,128,524 shares of the company’s stock worth $8,700,000 after buying an additional 301,564 shares during the last quarter. 41.42% of the stock is owned by institutional investors.

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Recommended Story: Google Finance Portfolio Tips and Tricks

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.